Colorectal cancer mRNA biomarker

Colorectal cancer mRNA biomarkers consist of gene transcripts whose presence and abundance offer a minimally invasive means to aid in the detection, prognosis, and treatment stratification of CRC patients. They include both single mRNAs and multigene signatures, such as the Consensus Molecular Subtypes (CMS) and panels (such as CEACAM5, KLK6, SLC35D3, POSTN, BIRC5, BMI1, and MLH1). mRNA profiling can be performed on tumor tissue, blood, or other specimen types, and is increasingly used to guide therapy (for example, selecting patients responsive to chemotherapy or targeted agents). Importantly, "colorectal cancer mRNA biomarkers" is not a single molecular target but a diagnostic/prognostic concept encompassing numerous specific genes and gene signatures. For structured data or therapeutic targeting, refer to individual mRNAs (e.g., KRAS, BRAF, BIRC5, MLH1) or gene panels, not the general category. If you are seeking a specific target molecule, such as an individual mRNA or gene product, specify the molecule of interest (e.g., "KRAS," "BIRC5"), as "colorectal cancer mRNA biomarkers" is too broad and does not align with standard definitions for therapeutic targets or receptors.

Other names

Colorectal cancer transcriptomic biomarkersCRC mRNA biomarkersgene expression biomarkers in colorectal cancer

Not applicable; mRNA biomarkers are not drug targets. However, drugs may be selected based on mRNA biomarker profiles indicating pathway activation or resistance